Liquidia (LQDA) Net Cash Flow Growth (1y) (2021 - 2026)
Liquidia (LQDA) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -117.27% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -167.84% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -290.21% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 270.63% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -367.42% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -7.60% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 272.00% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Liquidia | 6.38 Bn | 6.10 Bn | 160.92 Mn | 756.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 756.52% |
| Mar 31, 2026 | 577.70% |
| Dec 31, 2025 | 218.99% |
| Sep 30, 2025 | -122.34% |
| Jun 30, 2025 | 128.94% |
| Mar 31, 2025 | -109.06% |
| Dec 31, 2024 | -474.15% |
| Sep 30, 2024 | 695.40% |
| Jun 30, 2024 | -298.41% |
| Mar 31, 2024 | 6,470.33% |
| Dec 31, 2023 | 247.98% |
| Sep 30, 2023 | -116.87% |
| Jun 30, 2023 | -113.50% |
| Mar 31, 2023 | 276.33% |
| Dec 31, 2022 | 23.22% |
| Sep 30, 2022 | -43.90% |
| Jun 30, 2022 | 223.06% |
| Mar 31, 2022 | 102.57% |
| Dec 31, 2021 | 53.91% |
| Sep 30, 2021 | -106.85% |